REG - Craneware plc - FY25 Trading Update

CranewareAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nRSP1986Ra&default-theme=true

RNS Number : 1986R  Craneware plc  16 July 2025

Craneware plc

("Craneware" or the "Company")

 

FY25 Trading Update

Strong revenue growth and profitability ahead of expectations - accelerating
EBITDA, ARR and NRR

 

16 July 2025 - Craneware (AIM: CRW.L), a leader in healthcare financial
performance solutions, is pleased to provide an update on trading for the year
ended 30 June 2025 ("FY25").

 

The Group has experienced positive trading throughout the fiscal year,
delivering continued strong growth, and profitability ahead of consensus
market expectations.

Subject to audit, the Board expects a 12% increase in adjusted EBITDA(1) to
over $65m (FY24: $58.3m) delivered by revenue growth of 9% to $205.7m (FY24:
$189.3m). Annual Recurring Revenue ("ARR(2")) has grown by approximately 7% to
c.$184m (FY24: $172.0m). This follows continued sales momentum and the
transition of an initial proportion of Trisus Platform Partner revenues
associated with the Group's 340B software offerings into recurring revenue
streams, as anticipated. Net Revenue Retention has increased to 107% (FY24:
98%).

The Group continues to deliver high levels of operating cash conversion, which
have been used to invest in the product portfolio, reduce debt and interest
costs, with total bank debt reduced to $27.7m (FY24: $35.4m), whilst retaining
healthy total cash reserves of $55.9m (FY24: $34.6m).

Outlook

The Group anticipates that the ongoing drive within US healthcare to improve
efficiency and deliver value in healthcare will continue to provide a positive
market environment for Craneware's offerings.

The partnership with Microsoft is progressing well, raising the profile of The
Craneware Group and its AI-powered Trisus offerings with hospital CIOs across
the US, providing the basis for increased market penetration in future
periods. AI development in conjunction with Microsoft continues as planned.

Currently, a significant proportion of the Platform Partner revenue stream
reported is delivered from the Group's 340B associated "Shelter" offering.
This offering is based on current Craneware software and demonstrates how the
Group is proving successful at identifying new ways to utilise its extensive
data sets for the benefit of its customers. This programme continues to see
strong uptake across the 340B customer base and provides a strong backlog as
the Group enters FY26.

In addition, the Trisus Platform Partner revenue stream also included initial
third-party partner offerings. The Company continues to evaluate a number of
additional third-party partner offerings that can be hosted on the Trisus
platform, with another that was signed before the year end expected to go live
in H1 FY26.

The continued acceleration in EBITDA, ARR and NRR provides the Board with
confidence in the delivery of an accelerated revenue growth rate in FY26. The
strength of the Company's balance sheet and strong cash generation provide
Craneware with solid foundations as it executes on its growth strategy,
capitalising on its strategic position at the heart of the US healthcare
market.

Notice of Results

Craneware will announce results for the year ended 30 June 2025 on 15
September 2025.

Keith Neilson, CEO of Craneware plc, commented,

"We are pleased to see our growth rates accelerating and profitability exceed
expectations, with this year's performance supporting a move to sustainable,
double-digit growth. Our extensive data sets and the powerful insights we can
provide via our Trisus platform give our customers the means they need to
improve their operational and financial performance. We have a unique
capability to support our customers in their missions, and are seeing this
translate into continued strong expansion sales within our customer base and a
significant and growing base of recurring SaaS revenues. With continued strong
cash generation, and a strategic position as a source of independent data and
insights at the heart of the US healthcare market, we are excited by the
opportunity ahead, for us and our customers, and look to the future with
confidence."

(1) Adjusted EBITDA refers to earnings before interest, tax, depreciation,
amortisation, share based payments and exceptional  costs.

(2) Annual Recurring Revenue ("ARR") includes the annual value of licence and
transaction revenues as at 30 June 2025 that are subject to underlying
contracts.

 

 For further information, please contact:

 

 Craneware plc                                     +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications (Financial PR)      +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Sarah Peters      craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)                +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                  +44 (0)20 7597 5970
 Patrick Robb, Virginia Bull, James Smith
 ( )                                               ( )
 Berenberg (Joint Broker)                          +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Patrick Dolaghan

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation No 596/2014 which is part of English
Law by virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a Regulatory Information Service, this
information is considered to be in the public domain.

 

About The Craneware Group

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus(®) cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth.

As a trusted Microsoft partner, we provide future-ready solutions-including
the Best in KLAS Trisus Chargemaster-that simplify the complexities of
healthcare finance and operations. What sets us apart is our unique
combination of deep healthcare expertise and engineering excellence,
positioning us as a strategic partner rather than just a technology provider.

The Craneware Group empowers healthcare organizations to achieve sustainable
financial success while delivering better outcomes for the communities they
serve-today and in the future. Together, we are transforming the business of
healthcare.

Learn more at www.thecranewaregroup.com (http://www.thecranewaregroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTPKPBKCBKDKOD